全文获取类型
收费全文 | 1842655篇 |
免费 | 135870篇 |
国内免费 | 3049篇 |
专业分类
耳鼻咽喉 | 26141篇 |
儿科学 | 62563篇 |
妇产科学 | 49324篇 |
基础医学 | 269549篇 |
口腔科学 | 50450篇 |
临床医学 | 163453篇 |
内科学 | 362668篇 |
皮肤病学 | 41039篇 |
神经病学 | 139937篇 |
特种医学 | 71631篇 |
外国民族医学 | 718篇 |
外科学 | 279132篇 |
综合类 | 39246篇 |
现状与发展 | 3篇 |
一般理论 | 515篇 |
预防医学 | 137682篇 |
眼科学 | 41605篇 |
药学 | 138078篇 |
33篇 | |
中国医学 | 4412篇 |
肿瘤学 | 103395篇 |
出版年
2018年 | 19338篇 |
2017年 | 14733篇 |
2016年 | 16277篇 |
2015年 | 18241篇 |
2014年 | 25356篇 |
2013年 | 38577篇 |
2012年 | 52240篇 |
2011年 | 55218篇 |
2010年 | 32873篇 |
2009年 | 31145篇 |
2008年 | 52339篇 |
2007年 | 56036篇 |
2006年 | 56625篇 |
2005年 | 54474篇 |
2004年 | 53223篇 |
2003年 | 51288篇 |
2002年 | 50204篇 |
2001年 | 91580篇 |
2000年 | 94436篇 |
1999年 | 79565篇 |
1998年 | 21280篇 |
1997年 | 18927篇 |
1996年 | 19480篇 |
1995年 | 18471篇 |
1994年 | 17379篇 |
1993年 | 16071篇 |
1992年 | 62431篇 |
1991年 | 61327篇 |
1990年 | 59716篇 |
1989年 | 57601篇 |
1988年 | 52849篇 |
1987年 | 51678篇 |
1986年 | 48409篇 |
1985年 | 46123篇 |
1984年 | 34364篇 |
1983年 | 28930篇 |
1982年 | 16504篇 |
1981年 | 14905篇 |
1979年 | 30765篇 |
1978年 | 21447篇 |
1977年 | 18156篇 |
1976年 | 17137篇 |
1975年 | 18616篇 |
1974年 | 21750篇 |
1973年 | 20869篇 |
1972年 | 19375篇 |
1971年 | 17779篇 |
1970年 | 16921篇 |
1969年 | 15385篇 |
1968年 | 14108篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
81.
Long‐term safety of adalimumab in clinical trials in adult patients with Crohn's disease or ulcerative colitis 下载免费PDF全文
82.
83.
84.
Serum pepsinogen 1 and anti‐Helicobacter pylori IgG antibodies as predictors of gastric cancer risk in Finnish males 下载免费PDF全文
85.
86.
87.
Eyal Schwartzberg Joseph P. Nathan Sivan Avron Eli Marom 《Israel journal of health policy research》2018,7(1):59
The community pharmacy setting is a venue that is readily accessible to the public. In addition, it is staffed by a pharmacist, who is a healthcare provider, trained and capable of delivering comprehensive pharmaceutical care. As such, community pharmacists have a colossal opportunity to serve as key contributors to patients’ health by ensuring appropriate use of medications, preventing medication misadventures, identifying drug-therapy needs, as well as by being involved in disease management, screening, and prevention programs. This unique position gives the pharmacist the privilege and duty to serve patients in roles other than solely that of the stereotypical drug dispenser.Worldwide, as well as in Israel, pharmacists already offer a variety of pharmaceutical services and tend to patients’ and the healthcare system’s needs. This article provides examples of professional, clinical or other specialty services offered by community pharmacists around the world and in Israel and describes these interventions as well as the evidence for their efficacy. Examples of such activities which were recently introduced to the Israeli pharmacy landscape due to legislative changes which expanded the pharmacist’s scope of practice include emergency supply of medications, pharmacists prescribing, and influenza vaccination. Despite the progress already made, further expansion of these opportunities is warranted but challenging. Independent prescribing, as practiced in the United Kingdom or collaborative drug therapy management programs, as practiced in the United States, expansion of vaccination programs, or wide-spread recognition and reimbursement for medication therapy management (MTM) programs are unrealized opportunities. Obstacles such as time constraints, lack of financial incentives, inadequate facilities and technology, and lack of professional buy-in, and suggested means for overcoming these challenges are also discussed. 相似文献
88.
Javariya Aamir Syed Mustafa Ali Maged N. Kamel Boulos Naveed Anjum Muhammad Ishaq 《Health Policy and Technology》2018,7(1):88-97
Objective
The objective of this review is to identify enabling and inhibiting factors for mHealth adoption in low resource settings, by giving emphasis on the stakeholders representing the caregiving side. Another objective of this study is to support implementation agencies (governmental and non-governmental) in designing scalable mHealth interventions.Methods
A PEO (Population, Exposure, Outcome) approach was used to formulate the review question. A pre-defined search strategy was implemented; Google Scholar, PubMed and gray literature were searched using alternate terms for “mHealth”, “adoption” and “developing countries”. CASP [7] tools were used to assess the quality of selected evidence. After applying inclusion and exclusion criteria on search results and critical appraisal of the selected evidence, twelve studies were selected for the review.Results
Adoption factors operated at the levels of organization, facility-based service provider and frontline health worker. Engagement of end users during design phase, informed clinical decision making, utilization of mHealth evidence, employers’ tolerance of some personal use of devices, automation of tasks and user-friendliness of application are key enabling factors for mHealth adoption in developing countries. On the contrary, absence of national policy on mHealth, poor knowledge base on mHealth, using two systems in parallel, duplication of efforts, poor Internet connectivity and shortage of electricity are important inhibiting factors for mHealth adoption.Conclusions
The review provides an insight about the challenges and opportunities related to mHealth adoption in developing countries. Implementation agencies should give careful consideration to these factors before designing and deploying any mHealth-enabled intervention. It is also important to understand the concept of incremental innovation so that resources spent on pilot interventions are optimized and full potential is achieved. 相似文献89.
Camila L.P. Oliveira Stephanie Mattingly Ralf Schirrmacher Michael B. Sawyer Eugene J. Fine Carla M. Prado 《Journal of the Academy of Nutrition and Dietetics》2018,118(4):668-688
The predominant use of glucose anaerobically by cancer cells (Warburg effect) may be the most important characteristic the majority of these cells have in common and, therefore, a potential metabolic pathway to be targeted during cancer treatment. Because this effect relates to fuel oxidation, dietary manipulation has been hypothesized as an important strategy during cancer treatment. As such, the concept of a ketogenic diet (KD) in cancer emerged as a metabolic therapy (ie, targeting cancer cell metabolism) rather than a dietary approach. The therapeutic mechanisms of action of this high-fat, moderate-to-low protein, and very-low-carbohydrate diet may potentially influence cancer treatment and prognosis. Considering the lack of a dietetics-focused narrative review on this topic, we compiled the evidence related to the use of this diet in humans with diverse cancer types and stages, also focusing on the nutrition and health perspective. The use of KD in cancer shows potentially promising, but inconsistent, results. The limited number of studies and differences in study design and characteristics contribute to overall poor quality evidence, limiting the ability to draw evidence-based conclusions. However, the potential positive influences a KD may have on cancer treatment justify the need for well-designed clinical trials to better elucidate the mechanisms by which this dietary approach affects nutritional status, cancer prognosis, and overall health. The role of registered dietitian nutritionists is demonstrated to be crucial in planning and implementing KD protocols in oncology research settings, while also ensuring patients’ adherence and optimal nutritional status. 相似文献
90.
Amelia N. Deitchman Ravi Shankar Prasad Singh Hartmut Derendorf 《Journal of pharmaceutical sciences》2018,107(7):1754-1760
Nonlinear protein binding is traditionally thought of as an increasing fraction unbound with increasing total drug concentration. In the past several years, research into the protein binding of several tetracyclines has shown that an unexpected and counterintuitive phenomenon has been observed, specifically that of decreasing unbound drug fraction with increasing total concentrations of drug over certain concentration ranges. Although several studies of tigecycline have shown the importance calcium and its chelation may play in the protein-drug interaction, the potential clinical implications and relevance have not been explored. Here, we define typical and atypical nonlinear protein binding, overview protein binding theory, and discuss theoretical implications on pharmacokinetics. Using tigecycline as an example, in silico simulations and calculations show how when atypical nonlinear protein binding is not accounted for free drug exposure, and drug tissue penetration may be overestimated. It is important to revisit the impacts of nonlinearity in protein binding on clinical pharmacokinetics and pharmacodynamics, and ultimately, clinical efficacy. Although this phenomenon could potentially warrant clinical dose adjustment for certain compounds, it also presents a potential opportunity to exploit underlying mechanisms to develop new therapies and better understand molecular interactions of xenobiotics within the physiological system. 相似文献